Dialogues from the Dais: CVD Risk Reduction in the Hypertriglyceridemic Patient

1.50 CME
90 MINS
$0 FEE
SAVE
lipid activity

Overview

This highly interactive, CME-certified activity, presented in an innovative format, features 5 renowned lipid experts discussing hot topics in lipid management with a focus on the patient with elevated triglyceride levels. Topics include the remarkable clinical and biologic findings of the role of omega-3 fatty acids in reducing ASCVD events, making sense of recent guidelines, more evidence on the role of triglyceride-rich lipoproteins in ASCVD, and new horizons for lipid management. This activity is a well-balanced program of science and clinical practice, and the featured experts provide a diversity of experience and opinion on complex issues and cases that challenge healthcare providers who care for patients with elevated atherogenic cholesterol.

Provider Statement

medteliigence
Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.


Support Statement

This activity is supported by an independent educational grant from Amarin Pharma, Inc. 


Target Audience

This activity is designed to meet the educational needs of lipid specialists, diabetologists, clinical endocrinologists, internal medicine and primary care physicians, cardiologists, diabetes educators, and others who diagnose and treat patients at an increased residual risk for ASCVD worldwide.


Learning Objectives

Upon successful completion of this activity, participants should be better able to: 

  • Discuss the results and importance of REDUCE-IT and other recent cardiovascular outcomes trials that focus on reducing atherosclerotic cardiovascular disease (ASCVD) events beyond statin therapy
  • Apply evidence-based trial data and guidelines to lifestyle and therapeutic approaches to the management of care for patients with or at high risk of ASCVD events 
  • Discuss strategies to improve the knowledge, skills, and performance of the healthcare team

Faculty

Sergio Fazio, MD, PhD - Chair
William and Sonja Connor Chair of Preventive Cardiology
Professor of Medicine 
Director of Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, OR

Eliot A. Brinton, MD, FAHA, FNLA, FACE
President
Utah Lipid Center
Salt Lake City, UT

Michael Miller, MD, FACC, FAHA 
Professor of Cardiovascular Medicine, Epidemiology & Public Health
Director, Center for Preventive Cardiology
University of Maryland Medical Center
Baltimore, MD

Margo B. Minissian, PhD, ACNP, NEA-BC, FNLA, FAHA
Executive Director, Brawerman Institute, Nursing Education, Innovation, Practice Improvement and Research
Director, Postpartum Heart Health Program
Assistant Professor, Cardiology
Research Scientist
Barbra Streisand Women’s Heart Center at the Smidt Heart Institute
Geri and Richard Brawerman Nursing Institute
Cedars-Sinai Medical Center
Los Angeles, CA

John R. Nelson, MD, FACC, FNLA, FASNC
Director
California Cardiovascular Institute
Fresno, CA 


Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Learning Collaborative (GLC) and Medtelligence. GLC is accredited by the ACCME to provide continuing medical education for physicians. 


Credit Designation

Global Learning Collaborative designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Disclosures

In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. 

Faculty reports the following relationship(s)

Eliot A. Brinton, MD, FAHA, FNLA, FACE
Consulting Fees:
Amarin, AstraZeneca, 89Bio, DalCor, Esperion, Kowa, Medicure, Novartis
Commercial Interest Speakers Bureau:
Amarin, Amryt , Esperion, Medicure 

Sergio Fazio, MD, PhD
Consulting Fees:
Amarin Pharma, Inc., Amgen, AstraZeneca, 89Bio, Esperion, Kowa Pharmaceuticals America, Inc., Novartis, Novo Nordisk

Michael Miller, MD, FACC, FAHA
Consulting Fees:
Amarin

Margo B. Minissian, PhD, ACNP, NEA-BC, FNLA, FAHA
No relationships to disclose.

John R. Nelson, MD, FACC, FNLA, FASNC
Consulting Fees:
Amarin
Speaker Bureau:
Amarin, Amgen, Boehringer Ingelheim, Esperion
Ownership Interest: (stock)
Amarin, Amgen

Reviewers report the following relationship(s)

  • Ben Caref, PhD, has nothing to disclose.
  • Sue Grossman has nothing to disclose.
  • Kathy Wickman has nothing to disclose.

Copyright Statement

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

Reproduction Prohibited

Reproduction of this material is not permitted without written permission from the copyright owner.